MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2018.09.010

Медицинская библиотека · JACC. Cardiovascular interventions · 2018

Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial.

Chen Yundai, Gao Lei, Qin Qin, Chen Shaoliang, Zhang Jun, Chen Hui, Wang Lefeng, Jin Zening, Zheng Yang, Zhang Zheng, Li Hui, Li Xue, Fu Guosheng, Chen Lian, Sun Zhijun, Wang Yu, Jin Qinhua, Cao Feng, Guo Jun, Zhao Yanyan, Guan Changdong, Li Wei, Xu Bo, RESTORE ISR China Investigators

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАEquivalence TrialПеревод пока не подготовлен

Аннотация

OBJECTIVES

The aim of the present study was to evaluate the angiographic efficacy, clinical safety, and effectiveness of the Restore paclitaxel-coated balloon in a randomized trial designed to enable the approval of the new device in China.

BACKGROUND

Drug-coated balloon (DCB) angioplasty offers an effective treatment for in-stent restenosis. Restore is a new DCB with a SAFEPAX shellac-ammonium salt excipient that can avoid drug washing off during catheter delivery to the target lesion site.

METHODS

In the noninferiority RESTORE ISR China (Compare the Efficacy and Safety of RESTORE DEB and SeQuent Please in Chinese Patient With Coronary In-stent Restenosis) trial, eligible patients with first occurrence of drug-eluting stent ISR were randomized to the Restore DCB or SeQuent Please DCB in a 1:1 ratio stratified by diabetes. Angiographic and clinical follow-up was planned at 9 months and 1 year, respectively, in all patients. The study was powered for the primary endpoint of 9-month in-segment late loss.

RESULTS

Between May 2016 and July 2017, a total of 240 subjects at 12 sites were randomized to either the Restore group (n = 120) or the SeQuent Please group (n = 120). Nine-month in-segment late loss was 0.38 ± 0.50 mm with Restore versus 0.35 ± 0.47 mm with SeQuent Please; the 1-sided 97.5% upper confidence limit of the difference was 0.17 mm, achieving noninferiority of Restore compared with SeQuent Please (p for noninferiority = 0.02). Both DCBs had similar 1-year rates of target lesion failure (13.3% vs. 12.6%; p = 0.87).

CONCLUSIONS

In this head-to-head randomized trial, the Restore DCB was noninferior to the SeQuent Please DCB for the primary endpoint of 9-month in-segment late loss. (Compare the Efficacy and Safety of RESTORE DEB and SeQuent Please in Chinese Patient With Coronary In-stent Restenosis; NCT02944890).

Для цитирования: Chen Yundai, Gao Lei, Qin Qin, Chen Shaoliang, Zhang Jun, Chen Hui, Wang Lefeng, Jin Zening, Zheng Yang, Zhang Zheng, Li Hui, Li Xue, Fu Guosheng, Chen Lian, Sun Zhijun, Wang Yu, Jin Qinhua, Cao Feng, Guo Jun, Zhao Yanyan, Guan Changdong, Li Wei, Xu Bo, RESTORE ISR China Investigators. Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial.. JACC. Cardiovascular interventions. 2018. DOI: 10.1016/j.jcin.2018.09.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.